ArticleDigestive diseases and sciences2015
Autoimmune Markers Do Not Impact Clinical Presentation or Natural History of Steatohepatitis-Related Liver Disease.
Article in Digestive diseases and sciences, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 52 citations in OpenAlex.
- Article
- Autoantibodies are associated with worse outcomes in MASLD.JHEP reports : innovation in hepatology · 2025Article
- Anti-mitochondrial Antibodies in Patients with Elevated Alkaline Phosphatase/Gamma-glutamyl Transferase Levels: Hallmark or Bystander?Journal of clinical and translational hepatology · 2025Article
- Article
- Patients with AMA/anti-sp100/anti-gp210 Positivity and Cholestasis Can Manifest Conditions Beyond Primary Biliary Cholangitis.Journal of clinical and translational hepatology · 2025Article
- Commentary on Mariam Ragheb et al.Canadian liver journal · 2024Article
- Impact of hepatic steatosis on treatment response of autoimmune hepatitis: A retrospective multicentre analysis.Frontiers in immunology · 2022Article
- Immunoglobulin G in non-alcoholic steatohepatitis predicts clinical outcome: A prospective multi-centre cohort study.World journal of gastroenterology · 2021Article
- Biochemical assessment of metabolic associated fatty liver disease.Advances in laboratory medicine · 2021Article
- Significance of autoantibody seropositivity in children with obesity and non-alcoholic fatty liver disease.Pediatric obesity · 2021Article
- High-Titre ANA Positivity in NAFLD: An Uncommon Presentation of a Common Disease.European journal of case reports in internal medicine · 2020Article
- Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature.World journal of gastroenterology · 2019Review
- Direct-Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis.Hepatology communications · 2019Article
- A Young Man with Non-alcoholic Steatohepatitis and Serum Anti-mitochondrial Antibody Positivity.Internal medicine (Tokyo, Japan) · 2018Article
- Clinical characteristics of antimitochondrial antibody-positive patients at a safety net health care system in Arizona.BMJ open gastroenterology · 2017Article
- Correlation of Anti-mitochondrial Antibodies with Liver Histology and Outcomes.Digestive diseases and sciences · 2016Article
- Liver Injury Following Tinospora Cordifolia Consumption: Drug-Induced AIH, orJournal of clinical and experimental hepatologyArticle
- Autoantibody Positivity Has No Impact on Histological Parameters in Nonalcoholic Fatty Liver Diseases.Journal of clinical and experimental hepatologyArticle
Corrections and comments
- Commented on by
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimAutoimmune (AI) markers are reported in patients with steatohepatitis-related liver disease. However, their clinical significance is unclear.
methodsCharts of patients due to alcoholic liver disease (ALD) or nonalcoholic fatty liver disease (NAFLD) were stratified for antinuclear antigen (ANA > 1:80), antismooth muscle antibody (ASMA > 1:40), or antimitochondrial antibody (AMA > 1:20). Study outcomes were patient survival and complications of liver disease.
resultsOf 607 patients (401 NAFLD), information about AI markers was available for 398 (mean age 50 ± 15 year; 52% males; median body mass index (BMI) 38; 44% diabetic; 62% nonalcoholic steatohepatitis (NASH) as type of steatohepatitis; median MELD score 9). A total of 78 (19.6%) patients were positive for AI markers without differences for ALD versus NAFLD, cirrhosis versus no cirrhosis, and NASH versus no NASH. There were no differences for age, gender, BMI, cirrhosis at presentation, MELD score, endoscopic findings, and histology based on AI markers. Serum ALT was higher among patients with AI markers (65 ± 46 vs. 59 ± 66 IU/l; P = 0.048). Data remained unchanged on analyzing NAFLD patients. None of the 11 ANA-positive patients (1:640 in 4) showed findings of AI hepatitis. Biopsy in three AMA-positive patients showed mild bile duct damage in one patient. On median follow-up of about 3 years, there were no differences in liver disease outcomes (ascites, encephalopathy, variceal bleeding), hepatocellular carcinoma, transplantation, and survival.
conclusionsAutoimmune markers are frequently present in steatohepatitis-related liver disease patients. Their presence is an epiphenomenon without histological changes of autoimmune hepatitis. Further, their presence does not impact clinical presentation and follow-up outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.